Steatotic liver disease and HIV: an agenda for 2030

Lancet HIV. 2024 Aug;11(8):e561-e566. doi: 10.1016/S2352-3018(24)00097-3. Epub 2024 Jul 4.

Abstract

People living with HIV are particularly susceptible to developing metabolic disorders, including metabolic dysfunction-associated steatotic liver disease and other forms of SLD. However, people living with HIV have been historically excluded from clinical trials and large cohort studies of SLD. Therefore, our understanding of the risk factors and natural history of SLD in this population is poor. Moreover, relevant knowledge gaps on the epidemiology and barriers for adequate health care, such as stigma, hamper adequate responses to the ongoing HIV and SLD syndemic. This Viewpoint provides a comprehensive perspective on how to tackle SLD in people living with HIV by examining the role of social determinants of health in the development of liver disease and metabolic syndrome comorbidities among this population, emphasising the importance of prioritising SLD management, summarising the most urgent needs in the field, and offering recommendations for advancing research to fill key data gaps and protect liver health of people living with HIV.

Publication types

  • Review

MeSH terms

  • Comorbidity
  • Fatty Liver / epidemiology
  • HIV Infections* / complications
  • HIV Infections* / epidemiology
  • Humans
  • Metabolic Syndrome / epidemiology
  • Risk Factors
  • Social Determinants of Health
  • Social Stigma